Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)

34.49
Delayed Data
As of 3:59pm ET
 +1.76 / +5.38%
Today’s Change
31.77
Today|||52-Week Range
68.40
-39.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.0B

Company Description

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Contact Information

Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham Massachusetts 02451
P:(781) 209-6400
Investor Relations:
(781) 906-1112

Employees

Shareholders

Mutual fund holders42.71%
Individual stakeholders36.12%
Other institutional30.31%

Top Executives

Steven L. HoerterPresident, Chief Executive Officer & Director
Tucker KellyChief Financial Officer, Treasurer & Executive VP
Daniel L. FlynnChief Scientific Officer & Executive VP
Stephen B. RuddyChief Technical Officer
Matthew L. ShermanChief Medical Officer & Executive Vice President